lifestyle.nextmentors.com

Author: Invivyd

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 11, 2026
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 7, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2026
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

April 28, 2026
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

April 9, 2026
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

April 7, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 6, 2026
Invivyd Announces Presentation at the World Vaccine Congress Washington

March 30, 2026
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

March 5, 2026
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

March 5, 2026